


WHAT IS CLAIMED IS:

1. A compound of formula I:



I

wherein

X and Y are each CH, or one is CH and the other is N;

10 R1 and R2 are independently selected from

- (1) hydrogen and
- (2) C₁₋₄ alkyl;

R3 is selected from

- (1) hydrogen, and
- (2) C₁₋₄ alkyl optionally substituted with 1 to 4 groups selected from halogen, CO₂R^a, OR^a, COR^a and cyano;

R4 is selected from

- (1) hydrogen,
- (2) nitro,
- (3) halogen,
- (4) (CH₂)_nOR^a,
- (5) (CH₂)_nCO₂R^a,
- (6) (CH₂)_nCN,
- (7) (CH₂)_nNR^bRC,
- (8) (CH₂)_nNHC(O)CH₂CN,

- (9) CONR^bR^c, and
- (10) C₁₋₄ alkyl;

R₅ is a heterocycle selected from tetrahydrofuranyl, 2-oxo-4-azetidinyl, and a heteroaryl optionally substituted with C₁₋₄ alkyl wherein said heteroaryl is selected from isoxazolyl, furyl, thiadiazolyl, isothiazolyl, thiazolyl, imidazolyl, thienyl and oxazolyl;

5 R_{6a} is selected from

- (1) C₁₋₈ alkyl, optionally substituted with 1 to 5 groups independently selected from halogen, nitro, cyano, COR^a, SO₂R^d, CO₂R^a, NR^bR^c,
- 10 NR^bC(O)R^a, NHSO₂R^d, OR^a, OC(O)R^a, CONR^bR^c,
- (2) C₃₋₈ cycloalkyl,
- (3) C₂₋₈ alkenyl optionally substituted with CO₂R^a;
- (4) halogen,
- (5) OCF₃,
- 15 (6) cyano,
- (7) nitro,
- (8) NR^bR^c,
- (9) NR^bC(O)R^a,
- (10) NR^bCO₂R^{a'}, wherein R^{a'} is a non-hydrogen group selected
- 20 from R^a,
- (11) CO₂R^a,
- (12) COR^a,
- (13) C(O)NR^bR^c,
- (14) C(O)NHOR^a,
- 25 (15) OR^a,
- (16) OC(O)R^a,
- (17) S(O)_nR^{a'}, wherein R^{a'} is a non-hydrogen group selected from R^a,
- (18) SO₂NHRC,
- 30 (19) NHSO₂R^d,
- (20) C(=NOR^a)NR^bR^c,
- (21) C(=NOR^a)R^a, and
- (22) substituted or unsubstituted heterocycle where the heterocycle is selected from oxadiazole, tetrazole, triazole, pyrazole, oxazole, isoxazole, thiazole,

4,5-dihydro-oxazole, 4,5-dihydro-1,2,4-oxadiazol-5-one, and wherein said substituent is 1 to 3 groups independently selected from C₁₋₄alkyl optionally substituted with 1

to 5 halogen atoms, OR^a, or OC(O)R^a;

R_{6b} and R_{6c} are independently selected from

5 (1) hydrogen, and
 (2) a group from R_{6a}; with the proviso that not more than one of

R_{6a}, R_{6b}, and R_{6c} is a heterocycle;

R₇ is selected from

10 (1) hydrogen,
 (2) cyano,
 (3) nitro,
 (4) halogen,
 (5) OR^a,
 (6) CO₂R^a,
 15 (7) CONR^bR^c, and
 (8) C₁₋₄ alkyl;

R^a is selected from

20 (1) hydrogen,
 (2) C₁₋₄ alkyl,
 (3) C₃₋₆ cycloalkyl,
 (4) aryl, and
 (5) aryl-C₁₋₄ alkyl;

R^b and R^c are independently selected from

25 (1) hydrogen,
 (2) C₁₋₄ alkyl optionally substituted with OR^a,
 (3) C₃₋₆ cycloalkyl,
 (4) aryl, and
 (5) aryl-C₁₋₄ alkyl; or

R^b and R^c together with the nitrogen atom to which they are attached form a 5- or 6-membered ring optionally containing a heteroatom selected from NR^a, O and S;

R^d is selected from

(1) C₁₋₄ alkyl, optionally substituted with 1 to 3 halogen atoms,
 (2) aryl,
 (3) aryl-C₁₋₄ alkyl, and
 35 (4) NR^bR^c;

n is 0, 1 or 2
a pharmaceutically acceptable salt thereof.


2. A compound of Claim 1 wherein R₃ is hydrogen.
- 5 3. A compound of Claim 1 wherein R₃ is C₁₋₄ alkyl.
4. A compound of Claim 1 wherein R₄ is H or a 4-substituent.
- 10 5. A compound of Claim 1 wherein R₄ is H or a 4-substituent selected from C₁₋₄ alkyl and halogen.
6. A compound of Claim 1 wherein R₄ is 4-chloro or 4-methyl.
- 15 7. A compound of Claim 1 wherein R₅ is selected from 4-thiazolyl, 4-oxazolyl, 2-imidazolyl, 5-, 4- and 3-isoxazolyl, 3-, 4- and 5-isothiazolyl, 2- and 3-furyl, 2- and 3-thienyl, 1,2,5-thiadiazolyl, 5-methyl-3-isoxazolyl, 2-methyl-3-furyl, 5-methyl-4-oxazolyl, 5-methyl-4-isoxazolyl, 2-tetrahydrofuranyl, and 2-oxo-4-azetidinyl.
- 20 8. A compound of Claim 1 wherein R₅ is 2-oxo-4-azetidinyl, optionally methyl substituted 5- or 3-isoxazolyl, 3-furyl or 1,2,5-thiadiazol-3-yl.
9. A compound of Claim 1 wherein R₅ is 3- or 5-isoxazolyl.
- 25 10. A compound of Claim 1 wherein X and Y are both CH.
11. A compound of Claim 1 wherein one of X and Y is CH and the other is N.
- 30 12. A compound of Claim 1 wherein R_{6a} is a 2- (or ortho-) substituent selected from CO₂R^a, CONR^bR^c, CONHOR^a, cyano, and 1- and 2-methyltetrazol-5-yl.

13. A compound of Claim 12 wherein R_{6a} is selected from methyl carboxylate, N-methylcarboxamide, cyano and 1- and 2-methyltetrazol-5-yl.

14. A compound of Claim 1 wherein R_{6b} is hydrogen, halogen or 5 C₁₋₄alkyl.

15. A compound of Claim 1 wherein R_{6b} is hydrogen, fluoro, chloro, or methyl.

10 16. A compound of Claim 1 having the formula Ia:



Ia

wherein R₃, R₄, R₅, R_{6a}, R_{6b}, R₇, X and Y are as defined in Claim 1.

15

17. A compound of Claim 16 wherein at least two of R₃, R₄ and R_{6b} are non-hydrogen.

20

18. A compound of Claim 16 wherein R₃ is C₁₋₄ alkyl and R_{6b} is C₁₋₄ alkyl or halogen.

19. A compound of Claim 16 wherein R₄ is C₁₋₄ alkyl or halogen and R_{6b} is C₁₋₄ alkyl or halogen.

25


20. A compound of Claim 16 wherein R₃ is C₁₋₄ alkyl and R₄ is C₁₋₄ alkyl or halogen.

21. A compound of Claim 16 wherein R₃ is C₁₋₄ alkyl, R₄ is C₁₋₄ alkyl or halogen and R_{6b} is C₁₋₄ alkyl or halogen.

22. A compound of Claim 16 wherein R₃ is hydrogen or C₁₋₄ alkyl; R₄ is hydrogen, C₁₋₄ alkyl or halogen; R_{6a} is selected from CO₂R^a, CONR^bR^c, cyano, 1- and 2-methyltetrazol-5-yl; R_{6b} is hydrogen, or a 3- or 5-substituent selected from C₁₋₄alkyl and halogen; X and Y are each CH and R₇ is hydrogen, halogen or C₁₋₄ alkyl; or one of X and Y is CH and the other is N, and R₇ is hydrogen; with the proviso that at lease two of R₃, R₄ and R_{6b} are non-hydrogen.

10


23 A compound of Claim 1 represented by formula Ib:



15

wherein all the variables are as defined in Claim 1 and R_{3'} is C₁₋₄ alkyl optionally substituted with 1 to 4 groups selected from halogen, CO₂R^a, OR^a, COR^a and cyano.

24. A compound selected from:



R _{6a}	R _{6b}	R ₃	R ₄	R ₅
CO ₂ Me	3'-F	Me (R)	Me	5-isoxazolyl
2-Me-2H-tetrazol-5-yl	3'-F	Me (R)	Cl	5-isoxazolyl
2-Me-2H-tetrazol-5-yl	3'-F	Me (R)	Me	5-isoxazolyl
CONHMe	2'-F	Me (R)	Cl	5-isoxazolyl
CN	3'-F	Me (R)	Me	5-isoxazolyl
CO ₂ Me	3'-Cl	Me (R)	Cl	5-isoxazolyl
CN	3'-F	Me (R)	Cl	5-isoxazolyl
CONHMe	3'-F	Me (R)	Me	5-isoxazolyl
CO ₂ Me	3'-F	Me (R)	Cl	5-isoxazolyl
CO ₂ Me	3'-Cl	Me (R)	Me	5-isoxazolyl
CO ₂ Me	3'-F	Me (R)	H	
CO ₂ Me	3'-Cl	Me (R)	Cl	3-isoxazolyl
CO ₂ Me	5'-Me	Me (R)	Me	3-isoxazolyl
CO ₂ Me	5'-Cl	Me (R)	Me	3-furyl
CO ₂ Me	3'-Cl	Me (R)	H	3-isoxazolyl
1-Me-1H-tetrazol-5-yl	3'-F	Me (R)	Cl	5-isoxazolyl
CO ₂ Me	5'-Me	Me (R)	Me	3-furyl
CN	3'-F	Me (R)	Me	3-furyl
CN	3'-F	Me (R)	Me	1,2,5-thiadiazol-3-yl
CN	3'-F	Me (R)	Me	3-isothiazolyl
CONHOMe	H	H	Me	3-furyl
CO ₂ Me	H	H	Me	5-Me-3-isoxazolyl

R _{6a}	R _{6b}	R ₃	R ₄	R ₅
CO ₂ Me	H	H	H	3-furyl
CN	3'-F	Me (R)	Me	4-thiazolyl
CN	3'-F	Me (R)	Me	2-imidazolyl
CO ₂ Me	H	H	H	2-thienyl
CO ₂ Me	H	H	H	3-thienyl
CO ₂ Me	H	H	H	2-furyl
CO ₂ Me	H	H	H	2-tetrahydrofuranyl
CO ₂ Me	H	H	Me	2-methyl-3-furyl
CO ₂ Me	H	H	Me	5-methyl-4-oxazolyl
CO ₂ Me	H	H	Me	5-methyl-4-isoxazolyl

25. A pharmaceutical composition comprising a compound according to Claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

5

26. A method of treatment or prevention of pain and inflammation comprising a step of administering, to a subject in need of such treatment or prevention, an effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

10

27. A method of treatment of osteoarthritis, repetitive motion pain, dental pain, cancer pain, myofascial pain, muscular injury pain, fibromyalgia pain, perioperative pain comprising a step of administering, to a subject in need of such treatment, an effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

15

28. A method of treatment or prevention of inflammatory pain caused by chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, rhinitis, pancreatitis, cystitis (interstitial cystitis), uveitis, inflammatory skin disorders, 20 rheumatoid arthritis, edema resulting from trauma associated with burns, sprains or fracture, postsurgical intervention, osteoarthritis, rheumatic disease, teno-synovitis, or gout comprising a step of administering, to a subject in need of such treatment or

prevention, an effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

29. A method of treatment or prevention of pain associated with
5 angina, menstruation or cancer comprising a step of administering, to a subject in need of such treatment or prevention, an effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

30. A method of treatment of diabetic vasculopathy, post capillary
10 resistance, diabetic symptoms associated with insulitis, psoriasis, eczema, spasms of the gastrointestinal tract or uterus, Crohn's disease, ulcerative colitis, or pancreatitis comprising a step of administering, to a subject in need of such treatment, an effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

15 31. A method of treatment or prevention of pain caused by pneumoconiosis, including aluminosis, anthracosis, asbestosis, chalcosis, ptilosis, siderosis, silicosis, tabacosis, byssinosis, adult respiratory distress syndrome, bronchitis, allergic rhinitis, vasomotor rhinitis, liver disease, multiple sclerosis, 20 atherosclerosis, Alzheimer's disease, septic shock, cerebral edema, headache, migraine, closed head trauma, irritable bowel syndrome, or nephritis comprising a step of administering, to a subject in need of such treatment or prevention of pain, an effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.